BCAX (Bicara Therapeutics Inc) Cumulative Company Assets

Official company branding of Bicara Therapeutics Inc (BCAX)

The asset volume characteristics of Bicara Therapeutics Inc. (BCAX) are currently at 482.96. The business's financial model relies on external investments, as revenue remains volatile due to the conduct of new drug trials. Meanwhile, management possesses deep scientific expertise and successfully attracts capital, ensuring the transparent development of ficlatuzumab. Logistics are supported through certified biomaterial transport channels, eliminating disruptions at research centers.

Bicara Therapeutics Inc (BCAX) Aggregate Company Assets: for the period 09/14/2024 - 10/31/2026

Financial and market metric breakdowns for Bicara Bio (BCAX)

- stock quotes and analyst forecast:
Share Price bicara.com|BCAX - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation Bicara Corp|BCAX - Enterprise Value
- company book value details:
Book Value per Share Bicara Therapeutics|BCAX - Company Book Value|Capitalization to Book Value Ratio bicara.com|BCAX - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Bicara Therapeutics Inc.|BCAX - Long-Term Debt to Capital|Current Liabilities to Capital Bicara Corp|BCAX - Company Debts|Debt to Net Assets Ratio Bicara Corp|BCAX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Bicara Therapeutics|Quick Liquidity Indicator bicara.com
- earnings and market multiples details:
BCAX - Net Income
Basic company analysis:bicara.com (BCAX)
Core merchandise of Bicara Therapeutics

Total assets represent the aggregate of resources and capital, calculated reversely via ROA to determine the company's real cost basis. By analyzing the growth of assets and resources, an investor assesses the ability of Bicara Therapeutics Inc. (BCAX) to sustain costly R&D and patents for bifunctional antibodies under strict FDA oversight, where any decline in this indicator signals a risk of liquidity depletion.

Key competitors

Total Business Assets ONC|HALO (Halozyme) - Company Total Assets|Cumulative Company Assets Revolution Medicines Inc (RVMD)|Company Total Assets AAPG|Company Total Assets CG Oncology Therapeutics (CGON)|Aggregate Company Assets UroGen Pharma Ltd. URGN|PSNL: Total Business Assets|Erasca - Company Total Assets|Delcath Systems Inc (DCTH) - Cumulative Company Assets|YMAB: Company Total Assets|Company Assets Aura Corp (AURA)|Aggregate Company Assets Candel Therapeutics Inc.|ARAY: Aggregate Asset Value|Cumulative Company Assets SLS (SELLAS Life Sciences)|ACTU (Actuate Therapeutics Inc.) - Aggregate Asset Value|Company Total Assets CTOR (Citius Oncology, Inc)|HURA - Cumulative Company Assets|TARA: Cumulative Company Assets|FATE - Company Total Assets|aadibio.com (WHWK) - Aggregate Company Assets|TScan Therapeutics, Inc. - Aggregate Asset Value|CSBR (Champions Oncology Inc) - Company Total Assets|Company Assets XBiotech USA XBIT|Company Total Assets CVM|Aggregate Company Assets OSTX (ostherapies.com)|Company Total Assets RADX (Radiopharm Theranostics)|Company Total Asset Base Artiva Biotherapeutics Inc. (ARTV)|Adlai Nortye Limited - Company Total Assets|Veru Corporation (VERU) - Cumulative Company Assets|TPST: Company Total Assets|Xilio Therapeutics (XLO) - Company Total Assets|Aggregate Company Assets Renovaro Biosciences|MURA: Aggregate Asset Value|Company Total Assets KAPA|Company Total Assets onkuretherapeutics.com (OKUR)|CytoMed Therapeutics Limited - Cumulative Company Assets|Aggregate Asset Value CRIS|APLM: Cumulative Company Assets|Tharimmune Inc - Aggregate Business Assets|ADVB: Company Total Assets|Genprex Inc - Aggregate Asset Value|CLDI (Calidi Biotherapeutics Inc.) - Company Total Assets|Company Assets sunshinebiopharma.com SBFM|Aggregate Company Assets Xenetic Biosciences (XBIO)|SLRX (Salarius Pharmaceuticals Inc) - Aggregate Asset Value|Company Total Assets PPBT (Purple Biotech Corp)|Company Total Assets American Oncology Network Inc AONC|BGNE - Aggregate Company Assets|Total Asset Value of Company CKPT|ELEV: Company Total Assets|Company Assets iCAD (ICAD)|Cumulative Company Assets IKNA|Company Total Assets Notable Labs Corp|Cumulative Company Assets VIRX (Viracta Therapeutics)|Aggregate Business Assets MOR|Company Total Assets NAYA (NAYA Biosciences Inc.)|Company Total Asset Base Ascentage Pharma Group International (AAPGV)